[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ff5m14Bmb_YdbArH1hHAiEfZz3Bu1UqblyqfsQxWCEqg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":73,"rows":80},"Augusta University",[4],178,false,25,9,65901,8,123,[14,17,19,21,23,26,28,30],{"name":15,"count":16},"Hypertension",10,{"name":18,"count":16},"Obesity",{"name":20,"count":16},"Cardiovascular Diseases",{"name":22,"count":9},"Constipation",{"name":24,"count":25},"Heart Diseases",5,{"name":27,"count":25},"Fecal Incontinence",{"name":29,"count":25},"Blood Pressure",{"name":31,"count":32},"Cystic Fibrosis",4,[34,39,43,48,53,58,63,68],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT03583866","Adiposity and Endothelin Receptor Function","2025-12","Candesartan",{"nctId":40,"briefTitle":41,"date":37,"intervention":42},"NCT02116335","Endothelin Receptor Function and Acute Stress","Bosentan",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT02115724","Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)","2026-12","NMD; 0.4mg sub-lingual nitroglycerin spray",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04449198","Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1","2027-01-01","Resveratrol",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT06907992","A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia","2027-05-01","Antifungal treatment",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT06588413","Olanzapine 2.5 vs 5 mg in Quadruplet Nausea\u002FVomiting Prophylaxis Before High-Dose Melphalan","2027-10","Olanzapine",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT06142396","Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure","2027-11-01","Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT06843291","UNIVERSAL GENETIC TESTING OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (UGT)","2029-02","Genetic Testing for hematological malignancies",[74,75,76,77,78,79],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[81,132,153,174,196,218,239,259,281,320,346,370,395,420,438,464,482,508,531,561,579,597,615,640,664,697,715,742,767,792,826,851,876,915,941,968,994,1018,1036,1057,1075,1100,1118,1140,1165,1183,1209,1233,1258,1286,1304,1329,1347,1372,1396,1425,1456,1482,1504,1529,1553],{"intervention":62,"totalTrials":82,"cells":83},3,{"EARLY_PHASE1":84,"PHASE1":87,"PHASE2":89,"PHASE3":91,"PHASE4":115,"NA":130},{"trials":85,"activeCount":86},[],0,{"trials":88,"activeCount":86},[],{"trials":90,"activeCount":86},[],{"trials":92,"activeCount":114,"soonestReadout":61},[93,102],{"nctId":59,"briefTitle":60,"status":94,"phases":95,"primaryCompletion":61,"completion":61,"start":96,"enrollment":97,"conditions":98,"interventions":101},"RECRUITING",[77],"2024-09-17",172,[99,100],"Multiple Myeloma","Autologous Stem Cell Transplantation",[62],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":113},"NCT02635984","Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens","COMPLETED",[77],"2017-12","2015-11",108,[111,112],"Complications of Bone Marrow Transplant","Hematologic Neoplasms",[62],1,{"trials":116,"activeCount":86},[117],{"nctId":118,"briefTitle":119,"status":120,"phases":121,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":128},"NCT03857581","Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder","UNKNOWN",[78],"2021-07","2020-07",100,[126,127],"Psychosis","Substance Use Disorders",[129,62],"Clozapine",{"trials":131,"activeCount":86},[],{"intervention":38,"totalTrials":114,"cells":133},{"EARLY_PHASE1":134,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":151},{"trials":135,"activeCount":114,"soonestReadout":37},[136],{"nctId":35,"briefTitle":36,"status":137,"phases":138,"primaryCompletion":37,"completion":139,"start":140,"enrollment":8,"conditions":141,"interventions":142},"ACTIVE_NOT_RECRUITING",[74],"2026-01","2018-05-21",[15],[38],{"trials":144,"activeCount":86},[],{"trials":146,"activeCount":86},[],{"trials":148,"activeCount":86},[],{"trials":150,"activeCount":86},[],{"trials":152,"activeCount":86},[],{"intervention":67,"totalTrials":114,"cells":154},{"EARLY_PHASE1":155,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":170,"NA":172},{"trials":156,"activeCount":114,"soonestReadout":66},[157],{"nctId":64,"briefTitle":65,"status":94,"phases":158,"primaryCompletion":66,"completion":66,"start":159,"enrollment":160,"conditions":161,"interventions":163},[74],"2024-11-01",30,[99,162],"Renal Failure",[67],{"trials":165,"activeCount":86},[],{"trials":167,"activeCount":86},[],{"trials":169,"activeCount":86},[],{"trials":171,"activeCount":86},[],{"trials":173,"activeCount":86},[],{"intervention":52,"totalTrials":114,"cells":175},{"EARLY_PHASE1":176,"PHASE1":186,"PHASE2":188,"PHASE3":190,"PHASE4":192,"NA":194},{"trials":177,"activeCount":114,"soonestReadout":51},[178],{"nctId":49,"briefTitle":50,"status":94,"phases":179,"primaryCompletion":51,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":185},[74],"2027-07-01","2020-10-14",24,[184],"Type 1 Diabetes",[52],{"trials":187,"activeCount":86},[],{"trials":189,"activeCount":86},[],{"trials":191,"activeCount":86},[],{"trials":193,"activeCount":86},[],{"trials":195,"activeCount":86},[],{"intervention":47,"totalTrials":114,"cells":197},{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":206,"NA":208},{"trials":199,"activeCount":86},[],{"trials":201,"activeCount":86},[],{"trials":203,"activeCount":86},[],{"trials":205,"activeCount":86},[],{"trials":207,"activeCount":86},[],{"trials":209,"activeCount":114,"soonestReadout":46},[210],{"nctId":44,"briefTitle":45,"status":137,"phases":211,"primaryCompletion":46,"completion":212,"start":213,"enrollment":214,"conditions":215,"interventions":217},[79],"2027-01","2014-04",74,[216],"Cardiovascular Disease",[47],{"intervention":72,"totalTrials":114,"cells":219},{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":228,"NA":230},{"trials":221,"activeCount":86},[],{"trials":223,"activeCount":86},[],{"trials":225,"activeCount":86},[],{"trials":227,"activeCount":86},[],{"trials":229,"activeCount":86},[],{"trials":231,"activeCount":114,"soonestReadout":71},[232],{"nctId":69,"briefTitle":70,"status":233,"phases":234,"primaryCompletion":71,"completion":71,"start":235,"enrollment":124,"conditions":236,"interventions":238},"NOT_YET_RECRUITING",[79],"2025-02",[237],"Hematologic Disease",[72],{"intervention":42,"totalTrials":114,"cells":240},{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":247,"PHASE4":249,"NA":251},{"trials":242,"activeCount":86},[],{"trials":244,"activeCount":86},[],{"trials":246,"activeCount":86},[],{"trials":248,"activeCount":86},[],{"trials":250,"activeCount":86},[],{"trials":252,"activeCount":114,"soonestReadout":37},[253],{"nctId":40,"briefTitle":41,"status":137,"phases":254,"primaryCompletion":37,"completion":139,"start":255,"enrollment":256,"conditions":257,"interventions":258},[79],"2015-06",320,[15],[42],{"intervention":57,"totalTrials":114,"cells":260},{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":267,"PHASE4":269,"NA":271},{"trials":262,"activeCount":86},[],{"trials":264,"activeCount":86},[],{"trials":266,"activeCount":86},[],{"trials":268,"activeCount":86},[],{"trials":270,"activeCount":86},[],{"trials":272,"activeCount":114,"soonestReadout":56},[273],{"nctId":54,"briefTitle":55,"status":233,"phases":274,"primaryCompletion":56,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":280},[],"2027-12-31","2025-05-01",150,[279],"Candidemia",[57],{"intervention":282,"totalTrials":283,"cells":284},"Prazosin",2,{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":301,"PHASE4":303,"NA":318},{"trials":286,"activeCount":86},[],{"trials":288,"activeCount":86},[],{"trials":290,"activeCount":86},[291],{"nctId":292,"briefTitle":293,"status":105,"phases":294,"primaryCompletion":295,"completion":295,"start":296,"enrollment":297,"conditions":298,"interventions":300},"NCT02431936","Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress",[76],"2019-04-16","2015-04",50,[15,299,29],"Stress, Psychological",[282],{"trials":302,"activeCount":86},[],{"trials":304,"activeCount":86},[305],{"nctId":306,"briefTitle":307,"status":105,"phases":308,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":317},"NCT02199652","Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)",[78],"2017-09-01","2017-12-01","2014-03",20,[314,315,316],"Post Traumatic Stress Disorder","Suicidal Ideation","Nightmares",[282],{"trials":319,"activeCount":86},[],{"intervention":321,"totalTrials":114,"cells":322},"Pregabalin 150mg",{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":344},{"trials":324,"activeCount":86},[],{"trials":326,"activeCount":86},[],{"trials":328,"activeCount":86},[],{"trials":330,"activeCount":86},[],{"trials":332,"activeCount":86},[333],{"nctId":334,"briefTitle":335,"status":336,"phases":337,"primaryCompletion":338,"completion":338,"start":339,"enrollment":86,"conditions":340,"interventions":343},"NCT03714867","Pre-Operative Pregabalin for Post-Operative Pain in Head and Neck Cancer Surgery","WITHDRAWN",[78],"2020-07-07","2019-03-22",[341,342],"Head and Neck Cancer","Pain, Postoperative",[321],{"trials":345,"activeCount":86},[],{"intervention":347,"totalTrials":114,"cells":348},"Vitamin D",{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":368},{"trials":350,"activeCount":86},[],{"trials":352,"activeCount":86},[],{"trials":354,"activeCount":86},[],{"trials":356,"activeCount":86},[],{"trials":358,"activeCount":86},[359],{"nctId":360,"briefTitle":361,"status":105,"phases":362,"primaryCompletion":363,"completion":363,"start":364,"enrollment":16,"conditions":365,"interventions":367},"NCT01447173","Vitamin and Asthma Study",[78],"2011-09","2010-12",[366],"Asthma",[347],{"trials":369,"activeCount":86},[],{"intervention":371,"totalTrials":114,"cells":372},"Risperidone",{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":379,"PHASE4":381,"NA":393},{"trials":374,"activeCount":86},[],{"trials":376,"activeCount":86},[],{"trials":378,"activeCount":86},[],{"trials":380,"activeCount":86},[],{"trials":382,"activeCount":86},[383],{"nctId":384,"briefTitle":385,"status":105,"phases":386,"primaryCompletion":387,"completion":387,"start":388,"enrollment":389,"conditions":390,"interventions":392},"NCT00352196","Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study",[78],"2007-05","2001-11",23,[391],"Asperger's Disorder",[371],{"trials":394,"activeCount":86},[],{"intervention":396,"totalTrials":114,"cells":397},"Amiloride",{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":404,"PHASE4":406,"NA":418},{"trials":399,"activeCount":86},[],{"trials":401,"activeCount":86},[],{"trials":403,"activeCount":86},[],{"trials":405,"activeCount":86},[],{"trials":407,"activeCount":86},[408],{"nctId":409,"briefTitle":410,"status":120,"phases":411,"primaryCompletion":412,"start":413,"enrollment":414,"conditions":415,"interventions":417},"NCT01308983","Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension",[78],"2012-12","2010-09",32,[416],"Prehypertension",[396],{"trials":419,"activeCount":86},[],{"intervention":129,"totalTrials":114,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":430,"NA":436},{"trials":423,"activeCount":86},[],{"trials":425,"activeCount":86},[],{"trials":427,"activeCount":86},[],{"trials":429,"activeCount":86},[],{"trials":431,"activeCount":86},[432],{"nctId":118,"briefTitle":119,"status":120,"phases":433,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":434,"interventions":435},[78],[126,127],[129,62],{"trials":437,"activeCount":86},[],{"intervention":439,"totalTrials":114,"cells":440},"Eutectic Lidocaine Prilocaine",{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":447,"PHASE4":449,"NA":462},{"trials":442,"activeCount":86},[],{"trials":444,"activeCount":86},[],{"trials":446,"activeCount":86},[],{"trials":448,"activeCount":86},[],{"trials":450,"activeCount":86},[451],{"nctId":452,"briefTitle":453,"status":120,"phases":454,"primaryCompletion":455,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":460},"NCT04467125","Nexplanon Removal: Subcutaneous vs. Topical Lidocaine",[78],"2023-05-31","2020-01-06",40,[459],"Contraception",[439,461],"Subcutaneous Lidocaine",{"trials":463,"activeCount":86},[],{"intervention":461,"totalTrials":114,"cells":465},{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":474,"NA":480},{"trials":467,"activeCount":86},[],{"trials":469,"activeCount":86},[],{"trials":471,"activeCount":86},[],{"trials":473,"activeCount":86},[],{"trials":475,"activeCount":86},[476],{"nctId":452,"briefTitle":453,"status":120,"phases":477,"primaryCompletion":455,"completion":455,"start":456,"enrollment":457,"conditions":478,"interventions":479},[78],[459],[439,461],{"trials":481,"activeCount":86},[],{"intervention":483,"totalTrials":114,"cells":484},"Local anesthetics, IV sedation drugs and analgesics.",{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":506},{"trials":486,"activeCount":86},[],{"trials":488,"activeCount":86},[],{"trials":490,"activeCount":86},[],{"trials":492,"activeCount":86},[],{"trials":494,"activeCount":86},[495],{"nctId":496,"briefTitle":497,"status":120,"phases":498,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":503,"interventions":505},"NCT05467436","Evaluation of Pharmacogenomics Testing to Precision Prescriptions in Periodontal Patients",[78],"2022-11-01","2023-07-01","2020-01-01",35,[504],"Oral Surgeries",[483],{"trials":507,"activeCount":86},[],{"intervention":509,"totalTrials":114,"cells":510},"Amniotic Stem Cells and Collagen Matrix",{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":519,"NA":529},{"trials":512,"activeCount":86},[],{"trials":514,"activeCount":86},[],{"trials":516,"activeCount":86},[],{"trials":518,"activeCount":86},[],{"trials":520,"activeCount":86},[521],{"nctId":522,"briefTitle":523,"status":336,"phases":524,"primaryCompletion":525,"completion":525,"start":525,"enrollment":86,"conditions":526,"interventions":528},"NCT02314416","Stem Cells In Wound Healing With Collagen Matrix as a Carrier",[78],"2015-05",[527],"Wounds",[509],{"trials":530,"activeCount":86},[],{"intervention":532,"totalTrials":114,"cells":533},"Spinal fentanyl",{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":559},{"trials":535,"activeCount":86},[],{"trials":537,"activeCount":86},[],{"trials":539,"activeCount":86},[],{"trials":541,"activeCount":86},[],{"trials":543,"activeCount":86},[544],{"nctId":545,"briefTitle":546,"status":120,"phases":547,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":552,"interventions":555},"NCT03623256","Comparison of Intrathecal Versus Epidural Fentanyl on Fetal Bradycardia in Labor Combined Spinal Epidural Analgesia",[78],"2023-10-01","2023-10-31","2019-10-28",558,[553,554],"Labor Pain","Obstetric Pain",[532,556,557,558],"Spinal bupivacaine","Spinal Fentanyl and Bupivacaine","Epidural fentanyl \u002Fspinal bupivacaine",{"trials":560,"activeCount":86},[],{"intervention":556,"totalTrials":114,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":569,"PHASE4":571,"NA":577},{"trials":564,"activeCount":86},[],{"trials":566,"activeCount":86},[],{"trials":568,"activeCount":86},[],{"trials":570,"activeCount":86},[],{"trials":572,"activeCount":86},[573],{"nctId":545,"briefTitle":546,"status":120,"phases":574,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":575,"interventions":576},[78],[553,554],[532,556,557,558],{"trials":578,"activeCount":86},[],{"intervention":557,"totalTrials":114,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":589,"NA":595},{"trials":582,"activeCount":86},[],{"trials":584,"activeCount":86},[],{"trials":586,"activeCount":86},[],{"trials":588,"activeCount":86},[],{"trials":590,"activeCount":86},[591],{"nctId":545,"briefTitle":546,"status":120,"phases":592,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":593,"interventions":594},[78],[553,554],[532,556,557,558],{"trials":596,"activeCount":86},[],{"intervention":558,"totalTrials":114,"cells":598},{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":607,"NA":613},{"trials":600,"activeCount":86},[],{"trials":602,"activeCount":86},[],{"trials":604,"activeCount":86},[],{"trials":606,"activeCount":86},[],{"trials":608,"activeCount":86},[609],{"nctId":545,"briefTitle":546,"status":120,"phases":610,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":611,"interventions":612},[78],[553,554],[532,556,557,558],{"trials":614,"activeCount":86},[],{"intervention":616,"totalTrials":114,"cells":617},"pramipexole",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":626,"NA":638},{"trials":619,"activeCount":86},[],{"trials":621,"activeCount":86},[],{"trials":623,"activeCount":86},[],{"trials":625,"activeCount":86},[],{"trials":627,"activeCount":86},[628],{"nctId":629,"briefTitle":630,"status":105,"phases":631,"primaryCompletion":632,"completion":633,"start":634,"enrollment":312,"conditions":635,"interventions":637},"NCT00344994","SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole",[78],"2007-09","2010-04","2006-05",[636],"Restless Legs Syndrome",[616],{"trials":639,"activeCount":86},[],{"intervention":641,"totalTrials":114,"cells":642},"9-valent HPV vaccine",{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":647,"PHASE3":649,"PHASE4":651,"NA":662},{"trials":644,"activeCount":86},[],{"trials":646,"activeCount":86},[],{"trials":648,"activeCount":86},[],{"trials":650,"activeCount":86},[],{"trials":652,"activeCount":86},[653],{"nctId":654,"briefTitle":655,"status":120,"phases":656,"primaryCompletion":657,"completion":657,"start":658,"enrollment":124,"conditions":659,"interventions":661},"NCT04311528","9-valent HPV Vaccine in Postpartum Women",[78],"2021-12-31","2020-04-01",[660],"Human Papilloma Virus",[641],{"trials":663,"activeCount":86},[],{"intervention":665,"totalTrials":114,"cells":666},"Dolutegravir 50 MG",{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":671,"PHASE3":673,"PHASE4":675,"NA":695},{"trials":668,"activeCount":86},[],{"trials":670,"activeCount":86},[],{"trials":672,"activeCount":86},[],{"trials":674,"activeCount":86},[],{"trials":676,"activeCount":86},[677],{"nctId":678,"briefTitle":679,"status":105,"phases":680,"primaryCompletion":681,"completion":682,"start":683,"enrollment":16,"conditions":684,"interventions":693},"NCT04340388","Contribution of Dolutegravir to Obesity and Cardiovascular Disease",[78],"2022-06-17","2023-02-25","2020-09-17",[685,686,687,688,689,690,691,692],"HIV-1-infection","Antiviral Drug Adverse Reaction","Vascular Diseases","Cardiovascular Abnormalities","Abnormality of Adipose Tissue","Body Weight Changes","Body Fat Disorder","HIV-Associated Lipodystrophy Syndrome",[665,694],"Antiretroviral\u002FAnti HIV",{"trials":696,"activeCount":86},[],{"intervention":694,"totalTrials":114,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":705,"PHASE4":707,"NA":713},{"trials":700,"activeCount":86},[],{"trials":702,"activeCount":86},[],{"trials":704,"activeCount":86},[],{"trials":706,"activeCount":86},[],{"trials":708,"activeCount":86},[709],{"nctId":678,"briefTitle":679,"status":105,"phases":710,"primaryCompletion":681,"completion":682,"start":683,"enrollment":16,"conditions":711,"interventions":712},[78],[685,686,687,688,689,690,691,692],[665,694],{"trials":714,"activeCount":86},[],{"intervention":716,"totalTrials":114,"cells":717},"Zolpidem-CR",{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":724,"PHASE4":726,"NA":740},{"trials":719,"activeCount":86},[],{"trials":721,"activeCount":86},[],{"trials":723,"activeCount":86},[],{"trials":725,"activeCount":86},[],{"trials":727,"activeCount":86},[728],{"nctId":729,"briefTitle":730,"status":105,"phases":731,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":739},"NCT01689909","Reducing Suicidal Ideation Through Insomnia Treatment",[78],"2017-06","2018-01-01","2012-12-06",103,[737,738,315],"Insomnia","Depression",[716],{"trials":741,"activeCount":86},[],{"intervention":743,"totalTrials":114,"cells":744},"0.3% hypromellose",{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":751,"PHASE4":753,"NA":765},{"trials":746,"activeCount":86},[],{"trials":748,"activeCount":86},[],{"trials":750,"activeCount":86},[],{"trials":752,"activeCount":86},[],{"trials":754,"activeCount":86},[755],{"nctId":756,"briefTitle":757,"status":105,"phases":758,"primaryCompletion":759,"completion":759,"start":760,"enrollment":761,"conditions":762,"interventions":764},"NCT00598689","GenTeal in Perioperative Treatment of Laser Assisted in Situ Keratomileusis LASIK Patients",[78],"2009-10","2007-10",80,[763],"Corneal Epithelium Defect",[743],{"trials":766,"activeCount":86},[],{"intervention":768,"totalTrials":114,"cells":769},"OnabotulinumtoxinA",{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":774,"PHASE3":776,"PHASE4":778,"NA":790},{"trials":771,"activeCount":86},[],{"trials":773,"activeCount":86},[],{"trials":775,"activeCount":86},[],{"trials":777,"activeCount":86},[],{"trials":779,"activeCount":86},[780],{"nctId":781,"briefTitle":782,"status":120,"phases":783,"primaryCompletion":784,"completion":784,"start":785,"enrollment":124,"conditions":786,"interventions":789},"NCT05157295","Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial",[78],"2022-09-30","2022-01-01",[787,788],"Overactive Bladder Syndrome","Overactive Bladder",[768],{"trials":791,"activeCount":86},[],{"intervention":793,"totalTrials":283,"cells":794},"Ketamine",{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":801,"PHASE4":822,"NA":824},{"trials":796,"activeCount":86},[],{"trials":798,"activeCount":86},[],{"trials":800,"activeCount":86},[],{"trials":802,"activeCount":86},[803,813],{"nctId":804,"briefTitle":805,"status":336,"phases":806,"primaryCompletion":807,"completion":808,"start":809,"enrollment":86,"conditions":810,"interventions":812},"NCT03338205","The Role of Ketamine as an Adjuvant Therapy for Children With Acute Status Asthmaticus",[77],"2021-12","2022-01","2020-01",[811],"Status Asthmaticus",[793],{"nctId":814,"briefTitle":815,"status":120,"phases":816,"primaryCompletion":817,"completion":817,"start":818,"enrollment":312,"conditions":819,"interventions":821},"NCT02801292","Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease",[77],"2018-07","2016-07",[820],"Sickle Cell Disease",[793],{"trials":823,"activeCount":86},[],{"trials":825,"activeCount":86},[],{"intervention":827,"totalTrials":114,"cells":828},"Olanzapine, Omega 3, Vitamin E+C",{"EARLY_PHASE1":829,"PHASE1":831,"PHASE2":833,"PHASE3":835,"PHASE4":847,"NA":849},{"trials":830,"activeCount":86},[],{"trials":832,"activeCount":86},[],{"trials":834,"activeCount":86},[],{"trials":836,"activeCount":86},[837],{"nctId":838,"briefTitle":839,"status":840,"phases":841,"primaryCompletion":842,"start":843,"enrollment":312,"conditions":844,"interventions":846},"NCT00211562","Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids","TERMINATED",[77],"2006-01","2005-10",[845],"Schizophrenia",[827],{"trials":848,"activeCount":86},[],{"trials":850,"activeCount":86},[],{"intervention":852,"totalTrials":114,"cells":853},"fish oil",{"EARLY_PHASE1":854,"PHASE1":856,"PHASE2":858,"PHASE3":860,"PHASE4":872,"NA":874},{"trials":855,"activeCount":86},[],{"trials":857,"activeCount":86},[],{"trials":859,"activeCount":86},[],{"trials":861,"activeCount":86},[862],{"nctId":863,"briefTitle":864,"status":120,"phases":865,"primaryCompletion":866,"completion":866,"start":867,"enrollment":868,"conditions":869,"interventions":871},"NCT04386577","Effects of Vitamin D and Omega-3 Supplementation on Telomeres in VITAL",[77],"2021-04-30","2016-08-19",1054,[870],"Aging",[852],{"trials":873,"activeCount":86},[],{"trials":875,"activeCount":86},[],{"intervention":877,"totalTrials":283,"cells":878},"CT-011",{"EARLY_PHASE1":879,"PHASE1":881,"PHASE2":883,"PHASE3":909,"PHASE4":911,"NA":913},{"trials":880,"activeCount":86},[],{"trials":882,"activeCount":86},[],{"trials":884,"activeCount":86},[885,896],{"nctId":886,"briefTitle":887,"status":840,"phases":888,"primaryCompletion":889,"completion":889,"start":890,"enrollment":891,"conditions":892,"interventions":894},"NCT01420965","Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer",[76],"2016-12","2012-09",7,[893],"Prostatic Neoplasms",[877,895],"Cyclophosphamide",{"nctId":897,"briefTitle":898,"status":840,"phases":899,"primaryCompletion":900,"completion":900,"start":890,"enrollment":283,"conditions":901,"interventions":907},"NCT01313416","Gemcitabine and CT-011 for Resected Pancreatic Cancer",[76],"2017-01",[902,903,904,905,906],"Pancreatic Neoplasms","Cancer of the Pancreas","Neoplasms Pancreatic","Pancreatic Cancer","Pancreas Cancer",[877,908],"Gemcitabine",{"trials":910,"activeCount":86},[],{"trials":912,"activeCount":86},[],{"trials":914,"activeCount":86},[],{"intervention":916,"totalTrials":114,"cells":917},"Amifampridine",{"EARLY_PHASE1":918,"PHASE1":920,"PHASE2":922,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":919,"activeCount":86},[],{"trials":921,"activeCount":86},[],{"trials":923,"activeCount":86},[924],{"nctId":925,"briefTitle":926,"status":105,"phases":927,"primaryCompletion":928,"completion":929,"start":930,"enrollment":931,"conditions":932,"interventions":934},"NCT05123053","Firdapse for Post-BOTOX Vocal Weakness",[76],"2025-05-27","2025-09-23","2021-10-28",18,[933],"Vocal Weakness(Post-BOTOX Injection)",[916],{"trials":936,"activeCount":86},[],{"trials":938,"activeCount":86},[],{"trials":940,"activeCount":86},[],{"intervention":942,"totalTrials":114,"cells":943},"Escitalopram Therapy",{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":962,"PHASE4":964,"NA":966},{"trials":945,"activeCount":86},[],{"trials":947,"activeCount":86},[],{"trials":949,"activeCount":86},[950],{"nctId":951,"briefTitle":952,"status":105,"phases":953,"primaryCompletion":954,"completion":955,"start":956,"enrollment":957,"conditions":958,"interventions":961},"NCT00584571","SAT vs Escitalopram for Rectal Hypersensitivity",[76],"2015-12-31","2019-12-31","2007-12",55,[959,960],"Rectal Hypersensitivity","Irritable Bowel Syndrome-Constipation",[942],{"trials":963,"activeCount":86},[],{"trials":965,"activeCount":86},[],{"trials":967,"activeCount":86},[],{"intervention":969,"totalTrials":114,"cells":970},"mycophenolate mofetil",{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":988,"PHASE4":990,"NA":992},{"trials":972,"activeCount":86},[],{"trials":974,"activeCount":86},[],{"trials":976,"activeCount":86},[977],{"nctId":978,"briefTitle":979,"status":120,"phases":980,"primaryCompletion":981,"completion":982,"start":983,"enrollment":297,"conditions":984,"interventions":987},"NCT02432339","Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress",[75,76],"2019-11","2019-11-30","2014-04-22",[985,986],"Psychological Stress","Hypertension, Renal",[969],{"trials":989,"activeCount":86},[],{"trials":991,"activeCount":86},[],{"trials":993,"activeCount":86},[],{"intervention":995,"totalTrials":114,"cells":996},"Minocycline",{"EARLY_PHASE1":997,"PHASE1":999,"PHASE2":1001,"PHASE3":1012,"PHASE4":1014,"NA":1016},{"trials":998,"activeCount":86},[],{"trials":1000,"activeCount":86},[],{"trials":1002,"activeCount":86},[1003],{"nctId":1004,"briefTitle":1005,"status":105,"phases":1006,"primaryCompletion":889,"completion":889,"start":1007,"enrollment":1008,"conditions":1009,"interventions":1011},"NCT01805895","A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients",[75,76],"2013-02",16,[1010],"Intracerebral Hemorrhage",[995],{"trials":1013,"activeCount":86},[],{"trials":1015,"activeCount":86},[],{"trials":1017,"activeCount":86},[],{"intervention":895,"totalTrials":114,"cells":1019},{"EARLY_PHASE1":1020,"PHASE1":1022,"PHASE2":1024,"PHASE3":1030,"PHASE4":1032,"NA":1034},{"trials":1021,"activeCount":86},[],{"trials":1023,"activeCount":86},[],{"trials":1025,"activeCount":86},[1026],{"nctId":886,"briefTitle":887,"status":840,"phases":1027,"primaryCompletion":889,"completion":889,"start":890,"enrollment":891,"conditions":1028,"interventions":1029},[76],[893],[877,895],{"trials":1031,"activeCount":86},[],{"trials":1033,"activeCount":86},[],{"trials":1035,"activeCount":86},[],{"intervention":1037,"totalTrials":114,"cells":1038},"Irbesartan",{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1043,"PHASE3":1051,"PHASE4":1053,"NA":1055},{"trials":1040,"activeCount":86},[],{"trials":1042,"activeCount":86},[],{"trials":1044,"activeCount":86},[1045],{"nctId":1046,"briefTitle":1047,"status":120,"phases":1048,"primaryCompletion":982,"completion":982,"start":213,"enrollment":160,"conditions":1049,"interventions":1050},"NCT02386293","Effectiveness of Avapro in Obese Normotensive\u002FHypertensive African Americans",[76],[15,18,299,29],[1037],{"trials":1052,"activeCount":86},[],{"trials":1054,"activeCount":86},[],{"trials":1056,"activeCount":86},[],{"intervention":908,"totalTrials":114,"cells":1058},{"EARLY_PHASE1":1059,"PHASE1":1061,"PHASE2":1063,"PHASE3":1069,"PHASE4":1071,"NA":1073},{"trials":1060,"activeCount":86},[],{"trials":1062,"activeCount":86},[],{"trials":1064,"activeCount":86},[1065],{"nctId":897,"briefTitle":898,"status":840,"phases":1066,"primaryCompletion":900,"completion":900,"start":890,"enrollment":283,"conditions":1067,"interventions":1068},[76],[902,903,904,905,906],[877,908],{"trials":1070,"activeCount":86},[],{"trials":1072,"activeCount":86},[],{"trials":1074,"activeCount":86},[],{"intervention":1076,"totalTrials":114,"cells":1077},"BH4 5mg",{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1082,"PHASE3":1094,"PHASE4":1096,"NA":1098},{"trials":1079,"activeCount":86},[],{"trials":1081,"activeCount":86},[],{"trials":1083,"activeCount":86},[1084],{"nctId":1085,"briefTitle":1086,"status":105,"phases":1087,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1092},"NCT01772758","Cystic Fibrosis and Endothelial Function: At Rest and During Exercise",[76],"2016-06-21","2011-08",64,[31],[1076,1093],"BH4 20mg",{"trials":1095,"activeCount":86},[],{"trials":1097,"activeCount":86},[],{"trials":1099,"activeCount":86},[],{"intervention":1093,"totalTrials":114,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1112,"PHASE4":1114,"NA":1116},{"trials":1103,"activeCount":86},[],{"trials":1105,"activeCount":86},[],{"trials":1107,"activeCount":86},[1108],{"nctId":1085,"briefTitle":1086,"status":105,"phases":1109,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":1110,"interventions":1111},[76],[31],[1076,1093],{"trials":1113,"activeCount":86},[],{"trials":1115,"activeCount":86},[],{"trials":1117,"activeCount":86},[],{"intervention":1119,"totalTrials":114,"cells":1120},"Sildenafil",{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1125,"PHASE3":1134,"PHASE4":1136,"NA":1138},{"trials":1122,"activeCount":86},[],{"trials":1124,"activeCount":86},[],{"trials":1126,"activeCount":86},[1127],{"nctId":1128,"briefTitle":1129,"status":105,"phases":1130,"primaryCompletion":817,"completion":817,"start":213,"enrollment":1131,"conditions":1132,"interventions":1133},"NCT02057458","Blood Flow and Vascular Function in Cystic Fibrosis",[76],19,[31],[1119,1119],{"trials":1135,"activeCount":86},[],{"trials":1137,"activeCount":86},[],{"trials":1139,"activeCount":86},[],{"intervention":1141,"totalTrials":114,"cells":1142},"Cord Blood",{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1144,"activeCount":86},[],{"trials":1146,"activeCount":86},[],{"trials":1148,"activeCount":86},[1149],{"nctId":1150,"briefTitle":1151,"status":336,"phases":1152,"primaryCompletion":1153,"completion":1153,"start":1154,"enrollment":86,"conditions":1155,"interventions":1157},"NCT01072370","Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children",[75,76],"2019-02-28","2010-01",[1156],"Cerebral Palsy",[1141,1158],"Intravenous Sham",{"trials":1160,"activeCount":86},[],{"trials":1162,"activeCount":86},[],{"trials":1164,"activeCount":86},[],{"intervention":1158,"totalTrials":114,"cells":1166},{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1177,"PHASE4":1179,"NA":1181},{"trials":1168,"activeCount":86},[],{"trials":1170,"activeCount":86},[],{"trials":1172,"activeCount":86},[1173],{"nctId":1150,"briefTitle":1151,"status":336,"phases":1174,"primaryCompletion":1153,"completion":1153,"start":1154,"enrollment":86,"conditions":1175,"interventions":1176},[75,76],[1156],[1141,1158],{"trials":1178,"activeCount":86},[],{"trials":1180,"activeCount":86},[],{"trials":1182,"activeCount":86},[],{"intervention":1184,"totalTrials":114,"cells":1185},"Lubiprostone Control",{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1201,"PHASE3":1203,"PHASE4":1205,"NA":1207},{"trials":1187,"activeCount":86},[],{"trials":1189,"activeCount":86},[1190],{"nctId":1191,"briefTitle":1192,"status":105,"phases":1193,"primaryCompletion":1194,"completion":1194,"start":1195,"enrollment":1196,"conditions":1197,"interventions":1199},"NCT01190020","Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.",[75],"2012-03","2009-02",41,[1198],"Chronic Constipation, Methanogenesis",[1200,1184],"Lubiprostone",{"trials":1202,"activeCount":86},[],{"trials":1204,"activeCount":86},[],{"trials":1206,"activeCount":86},[],{"trials":1208,"activeCount":86},[],{"intervention":1210,"totalTrials":114,"cells":1211},"Bethanechol",{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1225,"PHASE3":1227,"PHASE4":1229,"NA":1231},{"trials":1213,"activeCount":86},[],{"trials":1215,"activeCount":86},[1216],{"nctId":1217,"briefTitle":1218,"status":105,"phases":1219,"primaryCompletion":1220,"completion":1220,"start":1221,"enrollment":25,"conditions":1222,"interventions":1224},"NCT01031043","Topical Bethanechol for Improvement of Esophageal Dysmotility",[75],"2012-04","2009-11",[1223],"Esophageal Dysmotility",[1210],{"trials":1226,"activeCount":86},[],{"trials":1228,"activeCount":86},[],{"trials":1230,"activeCount":86},[],{"trials":1232,"activeCount":86},[],{"intervention":1234,"totalTrials":114,"cells":1235},"Ambrisentan",{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1250,"PHASE3":1252,"PHASE4":1254,"NA":1256},{"trials":1237,"activeCount":86},[],{"trials":1239,"activeCount":86},[1240],{"nctId":1241,"briefTitle":1242,"status":105,"phases":1243,"primaryCompletion":1244,"completion":982,"start":1245,"enrollment":1246,"conditions":1247,"interventions":1249},"NCT02712346","The Role of Endothelin-1 in Sickle Cell Disease",[75],"2019-05-30","2015-09",26,[1248],"Sickle Cell Anemia",[1234],{"trials":1251,"activeCount":86},[],{"trials":1253,"activeCount":86},[],{"trials":1255,"activeCount":86},[],{"trials":1257,"activeCount":86},[],{"intervention":1259,"totalTrials":114,"cells":1260},"Cabozantinib",{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1278,"PHASE3":1280,"PHASE4":1282,"NA":1284},{"trials":1262,"activeCount":86},[],{"trials":1264,"activeCount":86},[1265],{"nctId":1266,"briefTitle":1267,"status":840,"phases":1268,"primaryCompletion":1269,"completion":1269,"start":1270,"enrollment":9,"conditions":1271,"interventions":1276},"NCT04173338","Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma",[75],"2022-03-28","2020-01-23",[1272,1273,1274,1275],"Non Small Cell Lung Cancer","Non-squamous Non-small-cell Lung Cancer","Urothelial Carcinoma","Malignant Mesothelioma",[1259,1277],"Pemetrexed",{"trials":1279,"activeCount":86},[],{"trials":1281,"activeCount":86},[],{"trials":1283,"activeCount":86},[],{"trials":1285,"activeCount":86},[],{"intervention":1277,"totalTrials":114,"cells":1287},{"EARLY_PHASE1":1288,"PHASE1":1290,"PHASE2":1296,"PHASE3":1298,"PHASE4":1300,"NA":1302},{"trials":1289,"activeCount":86},[],{"trials":1291,"activeCount":86},[1292],{"nctId":1266,"briefTitle":1267,"status":840,"phases":1293,"primaryCompletion":1269,"completion":1269,"start":1270,"enrollment":9,"conditions":1294,"interventions":1295},[75],[1272,1273,1274,1275],[1259,1277],{"trials":1297,"activeCount":86},[],{"trials":1299,"activeCount":86},[],{"trials":1301,"activeCount":86},[],{"trials":1303,"activeCount":86},[],{"intervention":1305,"totalTrials":114,"cells":1306},"Nivolumab 10 MG\u002FML Intravenous Solution [OPDIVO]",{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1321,"PHASE3":1323,"PHASE4":1325,"NA":1327},{"trials":1308,"activeCount":86},[],{"trials":1310,"activeCount":86},[1311],{"nctId":1312,"briefTitle":1313,"status":840,"phases":1314,"primaryCompletion":1315,"completion":1315,"start":456,"enrollment":16,"conditions":1316,"interventions":1319},"NCT04173325","Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer",[75],"2022-05-26",[1317,1318],"Small-cell Lung Cancer","Small Cell Lung Carcinoma",[1305,1320],"Irinotecan Injection [Camptosar]",{"trials":1322,"activeCount":86},[],{"trials":1324,"activeCount":86},[],{"trials":1326,"activeCount":86},[],{"trials":1328,"activeCount":86},[],{"intervention":1320,"totalTrials":114,"cells":1330},{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1339,"PHASE3":1341,"PHASE4":1343,"NA":1345},{"trials":1332,"activeCount":86},[],{"trials":1334,"activeCount":86},[1335],{"nctId":1312,"briefTitle":1313,"status":840,"phases":1336,"primaryCompletion":1315,"completion":1315,"start":456,"enrollment":16,"conditions":1337,"interventions":1338},[75],[1317,1318],[1305,1320],{"trials":1340,"activeCount":86},[],{"trials":1342,"activeCount":86},[],{"trials":1344,"activeCount":86},[],{"trials":1346,"activeCount":86},[],{"intervention":1348,"totalTrials":114,"cells":1349},"Morphine.",{"EARLY_PHASE1":1350,"PHASE1":1362,"PHASE2":1364,"PHASE3":1366,"PHASE4":1368,"NA":1370},{"trials":1351,"activeCount":86},[1352],{"nctId":1353,"briefTitle":1354,"status":120,"phases":1355,"primaryCompletion":1356,"completion":1356,"start":1357,"enrollment":1358,"conditions":1359,"interventions":1361},"NCT03926559","The Effect of Neuraxial Morphine (Duramorph) on Pain Control",[74],"2021-05-21","2019-04-01",125,[1360],"Perineal Tear",[1348],{"trials":1363,"activeCount":86},[],{"trials":1365,"activeCount":86},[],{"trials":1367,"activeCount":86},[],{"trials":1369,"activeCount":86},[],{"trials":1371,"activeCount":86},[],{"intervention":1373,"totalTrials":114,"cells":1374},"Cholecalciferol",{"EARLY_PHASE1":1375,"PHASE1":1386,"PHASE2":1388,"PHASE3":1390,"PHASE4":1392,"NA":1394},{"trials":1376,"activeCount":86},[1377],{"nctId":1378,"briefTitle":1379,"status":120,"phases":1380,"primaryCompletion":1245,"completion":1381,"start":213,"enrollment":182,"conditions":1382,"interventions":1385},"NCT02337257","Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans With Periodontal Disease",[74],"2015-12",[1383,1384],"Periodontal Disease","Vitamin D Deficiency",[1373],{"trials":1387,"activeCount":86},[],{"trials":1389,"activeCount":86},[],{"trials":1391,"activeCount":86},[],{"trials":1393,"activeCount":86},[],{"trials":1395,"activeCount":86},[],{"intervention":1200,"totalTrials":283,"cells":1397},{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1406,"PHASE3":1408,"PHASE4":1410,"NA":1412},{"trials":1399,"activeCount":86},[],{"trials":1401,"activeCount":86},[1402],{"nctId":1191,"briefTitle":1192,"status":105,"phases":1403,"primaryCompletion":1194,"completion":1194,"start":1195,"enrollment":1196,"conditions":1404,"interventions":1405},[75],[1198],[1200,1184],{"trials":1407,"activeCount":86},[],{"trials":1409,"activeCount":86},[],{"trials":1411,"activeCount":86},[],{"trials":1413,"activeCount":86},[1414],{"nctId":1415,"briefTitle":1416,"status":840,"phases":1417,"primaryCompletion":1418,"completion":1418,"start":1419,"enrollment":1420,"conditions":1421,"interventions":1424},"NCT00689026","Efficacy of Lubiprostone in Combination With Standard PEG Preparation",[79],"2010-03","2008-05",60,[1422,1423],"Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2",[1200],{"intervention":1426,"totalTrials":283,"cells":1427},"Tetrahydrobiopterin",{"EARLY_PHASE1":1428,"PHASE1":1430,"PHASE2":1432,"PHASE3":1443,"PHASE4":1445,"NA":1447},{"trials":1429,"activeCount":86},[],{"trials":1431,"activeCount":86},[],{"trials":1433,"activeCount":86},[1434],{"nctId":1435,"briefTitle":1436,"status":105,"phases":1437,"primaryCompletion":1438,"completion":1438,"start":1245,"enrollment":1439,"conditions":1440,"interventions":1442},"NCT02774226","Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease",[76],"2018-07-30",15,[1441],"Chronic Obstructive Pulmonary Disease (COPD)",[1426],{"trials":1444,"activeCount":86},[],{"trials":1446,"activeCount":86},[],{"trials":1448,"activeCount":86},[1449],{"nctId":1450,"briefTitle":1451,"status":105,"phases":1452,"primaryCompletion":255,"completion":255,"start":413,"enrollment":1420,"conditions":1453,"interventions":1455},"NCT01398943","Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)",[79],[1454],"Pulmonary Disease, Chronic Obstructive",[1426],{"intervention":1457,"totalTrials":114,"cells":1458},"Linaclotide",{"EARLY_PHASE1":1459,"PHASE1":1461,"PHASE2":1463,"PHASE3":1465,"PHASE4":1467,"NA":1469},{"trials":1460,"activeCount":86},[],{"trials":1462,"activeCount":86},[],{"trials":1464,"activeCount":86},[],{"trials":1466,"activeCount":86},[],{"trials":1468,"activeCount":86},[],{"trials":1470,"activeCount":86},[1471],{"nctId":1472,"briefTitle":1473,"status":105,"phases":1474,"primaryCompletion":1475,"completion":1476,"start":1477,"enrollment":1478,"conditions":1479,"interventions":1481},"NCT02078323","Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients",[79],"2017-10-04","2018-07-20","2014-02",39,[1480],"Irritable Bowel Syndrome With Constipation (IBS-C)",[1457],{"intervention":1483,"totalTrials":114,"cells":1484},"Gatorade, Pedialyte and New Solution",{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1491,"PHASE4":1493,"NA":1495},{"trials":1486,"activeCount":86},[],{"trials":1488,"activeCount":86},[],{"trials":1490,"activeCount":86},[],{"trials":1492,"activeCount":86},[],{"trials":1494,"activeCount":86},[],{"trials":1496,"activeCount":86},[1497],{"nctId":1498,"briefTitle":1499,"status":105,"phases":1500,"conditions":1501,"interventions":1503},"NCT00257374","Pedialyte or Gatorade for Viral Gastroenteritis in Adults: a Randomized, Controlled Trial",[79],[1502],"Gastroenteritis",[1483],{"intervention":1505,"totalTrials":114,"cells":1506},"Cannabidiol",{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1513,"PHASE4":1515,"NA":1517},{"trials":1508,"activeCount":86},[],{"trials":1510,"activeCount":86},[],{"trials":1512,"activeCount":86},[],{"trials":1514,"activeCount":86},[],{"trials":1516,"activeCount":86},[],{"trials":1518,"activeCount":86},[1519],{"nctId":1520,"briefTitle":1521,"status":1522,"phases":1523,"primaryCompletion":1524,"completion":809,"start":1525,"conditions":1526,"interventions":1528},"NCT02397863","Epidiolex and Drug Resistant Epilepsy in Children","AVAILABLE",[],"2019-12","2014-12",[1527],"Epilepsy",[1505],{"intervention":1530,"totalTrials":114,"cells":1531},"(Cystagon) Cysteamine Bitartrate",{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1538,"PHASE4":1540,"NA":1542},{"trials":1533,"activeCount":86},[],{"trials":1535,"activeCount":86},[],{"trials":1537,"activeCount":86},[],{"trials":1539,"activeCount":86},[],{"trials":1541,"activeCount":86},[],{"trials":1543,"activeCount":86},[1544],{"nctId":1545,"briefTitle":1546,"status":840,"phases":1547,"primaryCompletion":1548,"completion":1548,"start":1549,"enrollment":82,"conditions":1550,"interventions":1552},"NCT01139125","An Open Trial of Cysteamine Treatment in Schizophrenia",[79],"2012-06","2009-09",[845,1551],"Schizoaffective",[1530],{"intervention":1554,"totalTrials":114,"cells":1555},"Oral Antibiotic and Oral Rinse",{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1562,"PHASE4":1564,"NA":1566},{"trials":1557,"activeCount":86},[],{"trials":1559,"activeCount":86},[],{"trials":1561,"activeCount":86},[],{"trials":1563,"activeCount":86},[],{"trials":1565,"activeCount":86},[],{"trials":1567,"activeCount":86},[1568],{"nctId":1569,"briefTitle":1570,"status":105,"phases":1571,"primaryCompletion":1572,"completion":1572,"start":1194,"enrollment":931,"conditions":1573,"interventions":1575},"NCT01568944","Role of Infected Blood Dendritic Cells in Heart Disease Risk",[79],"2014-09",[1574],"Chronic Periodontitis",[1554]]